90 related articles for article (PubMed ID: 7803769)
21. [Octreotide scintigraphy for the diagnosis of active Graves' ophthalmopathy].
Ardjomand N; Esche G; Fellner P; Lindner S; Panzitt M; Aigner R; Langmann A
Ophthalmologe; 2003 Dec; 100(12):1049-53. PubMed ID: 14704818
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease.
Colao A; Pivonello R; Lastoria S; Faggiano A; Ferone D; Lombardi G; Fenzi G
Eur J Endocrinol; 2000 Oct; 143 Suppl 1():S35-42. PubMed ID: 11068938
[No Abstract] [Full Text] [Related]
23. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2005 Apr; 15(4):358-63. PubMed ID: 15876160
[TBL] [Abstract][Full Text] [Related]
24. Octreoscan in thyroid-associated ophthalmopathy.
Krassas GE
Thyroid; 2002 Mar; 12(3):229-31. PubMed ID: 11952044
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
[TBL] [Abstract][Full Text] [Related]
26. Indium-111 octreotide in Graves' disease and in the evaluation of active exophthalmos.
Mansi L; Rambaldi PF; Bizzarro A; Panza N; Di Martino S; De Bellis A; Del Vecchio E
Q J Nucl Med; 1995 Jun; 39(2):105-10. PubMed ID: 8574802
[TBL] [Abstract][Full Text] [Related]
27. [Immunological imaging using tagged octreotide].
Cascini GL; Cuccurullo V; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):129-33. PubMed ID: 11753235
[TBL] [Abstract][Full Text] [Related]
28. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
[TBL] [Abstract][Full Text] [Related]
29. Graves' dermopathy: does octreotide scintigraphy predict the response to octreotide treatment?
Kuyvenhoven JP; van der Pijl JW; Goslings BM; Wiersinga WM
Thyroid; 1996 Oct; 6(5):385-9. PubMed ID: 8936660
[TBL] [Abstract][Full Text] [Related]
30. Octreotide scintigraphy in thyroidal and orbital Graves' disease.
Wiersinga WM; Gerding MN; Prummel MF; Krenning EP
Thyroid; 1998 May; 8(5):433-6. PubMed ID: 9623738
[No Abstract] [Full Text] [Related]
31. Somatostatin receptor scintigraphy for optic nerve sheath meningiomas.
Saeed P; Tanck MW; Freling N; Baldeschi L; Mourits MP; Bennink RJ
Ophthalmology; 2009 Aug; 116(8):1581-6. PubMed ID: 19500849
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptor imaging of endocrine gastrointestinal tumors.
Krenning EP; Kwekkeboom DJ; Oei HY; Reubi JC; van Hagen PM; Kooij PP; Reijs AE; Lamberts SW
Schweiz Med Wochenschr; 1992 Apr; 122(17):634-7. PubMed ID: 1350377
[TBL] [Abstract][Full Text] [Related]
33. [Computer tomographic diagnosis of endocrine orbitopathy].
Voigt B; Kretzschmar K; Wende S
Radiologe; 1984 Oct; 24(10):468-71. PubMed ID: 6548827
[TBL] [Abstract][Full Text] [Related]
34. Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs.
Cozma I; Zhang L; Uddin J; Lane C; Rees A; Ludgate M
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1630-5. PubMed ID: 17848636
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
[TBL] [Abstract][Full Text] [Related]
36. [Somatostatin receptor genes expression and effects of octreotide on orbital fibroblasts from Graves' ophthalmopathy].
Pasquali D; Notaro A; Esposito D; Vassallo P; Bonavolontà G; Bellastella A; Sinisi AA
Minerva Endocrinol; 2001 Sep; 26(3):175-9. PubMed ID: 11753241
[TBL] [Abstract][Full Text] [Related]
37. [Scintigraphy detection of somatostatin receptor in tumor diagnosis].
Parkkila S; Ahonen A; Leinonen L; Salmela P
Duodecim; 1996; 112(7):589-97. PubMed ID: 10592623
[No Abstract] [Full Text] [Related]
38. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.
Scheidhauer K; Hildebrandt G; Luyken C; Schomäcker K; Klug N; Schicha H
Horm Metab Res Suppl; 1993; 27():59-62. PubMed ID: 8330874
[TBL] [Abstract][Full Text] [Related]
39. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
Wémeau JL; Caron P; Beckers A; Rohmer V; Orgiazzi J; Borson-Chazot F; Nocaudie M; Perimenis P; Bisot-Locard S; Bourdeix I; Dejager S
J Clin Endocrinol Metab; 2005 Feb; 90(2):841-8. PubMed ID: 15562016
[TBL] [Abstract][Full Text] [Related]
40. [Two cases of orbital myositis with 67Ga accumulation in the orbits].
Tateishi T; Tanaka K; Mitsuo K
Rinsho Shinkeigaku; 2006 Jan; 46(1):55-8. PubMed ID: 16541796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
